We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With TransMedics (TMDX) Q3 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that TransMedics (TMDX - Free Report) will announce quarterly earnings of $0.28 per share in its forthcoming report, representing an increase of 333.3% year over year. Revenues are projected to reach $114.22 million, increasing 71.9% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Net revenue by OCS product- OCS Lung net revenue' should arrive at $4.71 million. The estimate indicates a change of +26.6% from the prior-year quarter.
Analysts predict that the 'Net revenue by OCS product- OCS Liver net revenue' will reach $77.47 million. The estimate indicates a year-over-year change of +87.5%.
It is projected by analysts that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $30.50 million. The estimate suggests a change of +60.9% year over year.
The average prediction of analysts places 'Geographic Revenues- United States' at $108.65 million. The estimate suggests a change of +82% year over year.
The combined assessment of analysts suggests that 'Geographic Revenues- All other countries' will likely reach $4.03 million. The estimate indicates a change of -6.2% from the prior-year quarter.
Shares of TransMedics have experienced a change of -21.2% in the past month compared to the +2.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMDX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With TransMedics (TMDX) Q3 Earnings: Wall Street's Insights on Key Metrics
Analysts on Wall Street project that TransMedics (TMDX - Free Report) will announce quarterly earnings of $0.28 per share in its forthcoming report, representing an increase of 333.3% year over year. Revenues are projected to reach $114.22 million, increasing 71.9% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain TransMedics metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Net revenue by OCS product- OCS Lung net revenue' should arrive at $4.71 million. The estimate indicates a change of +26.6% from the prior-year quarter.
Analysts predict that the 'Net revenue by OCS product- OCS Liver net revenue' will reach $77.47 million. The estimate indicates a year-over-year change of +87.5%.
It is projected by analysts that the 'Net revenue by OCS product- OCS Heart net revenue' will reach $30.50 million. The estimate suggests a change of +60.9% year over year.
The average prediction of analysts places 'Geographic Revenues- United States' at $108.65 million. The estimate suggests a change of +82% year over year.
The combined assessment of analysts suggests that 'Geographic Revenues- All other countries' will likely reach $4.03 million. The estimate indicates a change of -6.2% from the prior-year quarter.
View all Key Company Metrics for TransMedics here>>>
Shares of TransMedics have experienced a change of -21.2% in the past month compared to the +2.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TMDX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>